KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Assets (2016 - 2025)

BeOne Medicines (ONC) has disclosed Non-Current Assets for 11 consecutive years, with $2.0 billion as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 1.33% to $2.0 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 billion, a 282.18% increase, with the full-year FY2025 number at $2.0 billion, up 1.33% from a year prior.
  • Non-Current Assets was $2.0 billion for Q4 2025 at BeOne Medicines, up from -$5.7 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.0 billion in Q4 2025 to a low of -$5.7 billion in Q3 2025.
  • A 5-year average of -$70.4 million and a median of $1.0 billion in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: soared 121.37% in 2021, then plummeted 395.16% in 2025.
  • BeOne Medicines' Non-Current Assets stood at $1.0 billion in 2021, then increased by 13.58% to $1.2 billion in 2022, then skyrocketed by 36.65% to $1.6 billion in 2023, then rose by 20.44% to $1.9 billion in 2024, then rose by 1.33% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ONC's Non-Current Assets are $2.0 billion (Q4 2025), -$5.7 billion (Q3 2025), and $1.9 billion (Q4 2024).